Dr. Saad A. Khan

Radiology
1401 E State St, 
Rockford, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Referral may be required
Before you request
1401 E State St, 
Rockford, IL 

Overview

Saad Khan is a Radiologist practicing medicine in Rockford, Illinois.

His clinical expertise encompasses Tenosynovitis and Pleurisy.

Dr. Khan is board certified in Radiology. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 20 clinical trials. Dr. Khan is currently accepting new patients.

Specialties

Radiology

Licenses

Student in an Organized Health Care Education/Training Program in IL

Board Certifications

Radiology

Hospital Affiliations

Saint Anthony Medical Center
Uw Health
Advocate Good Samaritan Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

SwedishAmerican Hospital
1401 E State St, Rockford, IL 61104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase II Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Phase II Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: August 17, 2026
Intervention Type: Drug
Study Phase: Phase 2
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

1 Total Publications

Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus.
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: December 01, 2016
Similar Doctors
Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required
Before you request

Office

8777 Velocity Dr, 
Machesney Park, IL 
 (6.0 miles away)
888-819-0808
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Cohen is a Radiologist practicing medicine in Machesney Park, Illinois. Dr. Cohen is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Atypical Hemolytic Uremic Syndrome (aHUS), Osteolysis Syndrome Recessive, Febrile Neutropenia, Aortic Valve Replacement, and Percutaneous Coronary Intervention (PCI). Dr. Cohen is currently accepting new patients.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

SwedishAmerican Hospital

1401 E State St, 
Rockford, IL 
 (0.1 miles away)
779-696-4400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Kozlov is a Radiologist practicing medicine in Rockford, Illinois. Dr. Kozlov is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Ascites, Pleurisy, Pleural Effusion, Bone Marrow Aspiration, and Bone Graft. Dr. Kozlov is currently accepting new patients.

Expertise in
1
conditions
Dr. Rimas P. Gilvydis
Radiology | Interventional Radiology
Expertise in
1
conditions
Dr. Rimas P. Gilvydis
Radiology | Interventional Radiology
Referral may be required
Before you request

Office

2990 N Perryville Rd Unit 3400, 
Rockford, IL 
 (4.0 miles away)
815-316-8346
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rimas Gilvydis is a Radiologist and an Interventional Radiologist practicing medicine in Rockford, Illinois. Dr. Gilvydis is highly rated in 1 condition, according to our data. His clinical expertise encompasses Varicose Veins. Dr. Gilvydis is currently accepting new patients.

Frequently Asked Questions about Dr. Saad A. Khan

How do I make an appointment with Dr. Saad A. Khan?

You can book an appointment with Dr. Saad A. Khan by calling their office at 779-696-4400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Saad A. Khan a top-rated expert for Tenosynovitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Saad A. Khan is classified as an Experienced expert for Tenosynovitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Saad A. Khan specialize in?

While Dr. Saad A. Khan is a Radiology, they have specific expertise in Tenosynovitis, Pleurisy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiology.

Does Dr. Saad A. Khan participate in research or clinical trials?

Yes. Dr. Saad A. Khan has published 1 articles and abstracts on conditions like Tenosynovitis. You can view a list of Dr. Saad A. Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Saad A. Khan accept my insurance?

Dr. Saad A. Khan accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 779-696-4400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile